[{"address1": "9 Cedarbrook Drive", "city": "Cranbury", "state": "NJ", "zip": "08512", "country": "United States", "phone": "609 659 8001", "website": "https://www.rocketpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.", "fullTimeEmployees": 268, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gaurav D. Shah M.D.", "age": 48, "title": "CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 1013566, "exercisedValue": 0, "unexercisedValue": 17280444}, {"maxAge": 1, "name": "Ms. Kinnari  Patel M.B.A., Pharm.D.", "age": 44, "title": "Head of R&D, President & COO", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 846110, "exercisedValue": 0, "unexercisedValue": 8160658}, {"maxAge": 1, "name": "Mr. Mayo  Pujols", "age": 54, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 877691, "exercisedValue": 0, "unexercisedValue": 963608}, {"maxAge": 1, "name": "Mr. Jonathan  Schwartz M.D.", "age": 59, "title": "Chief Medical & Gene Therapy Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 657870, "exercisedValue": 627822, "unexercisedValue": 4606789}, {"maxAge": 1, "name": "Mr. Aaron  Ondrey", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin Louis Wilson J.D.", "age": 47, "title": "General Counsel, Chief Compliance Officer & Chief Corporate Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 149950, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kevin  Giordano", "title": "Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Isabel  Carmona J.D.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gayatri R. Rao J.D., M.D.", "title": "Senior VP of Clinical Safety & Chief Regulatory Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Raj  Prabhakar M.B.A.", "age": 49, "title": "Chief Business Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 619127, "exercisedValue": 0, "unexercisedValue": 55650}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 6, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 17.85, "open": 17.86, "dayLow": 17.59, "dayHigh": 18.55, "regularMarketPreviousClose": 17.85, "regularMarketOpen": 17.86, "regularMarketDayLow": 17.59, "regularMarketDayHigh": 18.55, "beta": 1.09, "forwardPE": -6.9661655, "volume": 730475, "regularMarketVolume": 730475, "averageVolume": 841066, "averageVolume10days": 641330, "averageDailyVolume10Day": 641330, "bid": 18.53, "ask": 18.57, "bidSize": 200, "askSize": 400, "marketCap": 1685783552, "fiftyTwoWeekLow": 15.27, "fiftyTwoWeekHigh": 32.525, "fiftyDayAverage": 21.0117, "twoHundredDayAverage": 24.582525, "currency": "USD", "enterpriseValue": 1370892032, "floatShares": 70898397, "sharesOutstanding": 90975904, "sharesShort": 10923156, "sharesShortPriorMonth": 9642489, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1201, "heldPercentInsiders": 0.03417, "heldPercentInstitutions": 1.0462899, "shortRatio": 14.43, "shortPercentOfFloat": 0.2549, "bookValue": 4.229, "priceToBook": 4.3816504, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -253259008, "trailingEps": -2.77, "forwardEps": -2.66, "pegRatio": -0.16, "lastSplitFactor": "1:4", "lastSplitDate": 1515110400, "enterpriseToEbitda": -5.243, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "RCKT", "underlyingSymbol": "RCKT", "shortName": "Rocket Pharmaceuticals, Inc.", "longName": "Rocket Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1424269800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "4162d708-cd89-3d56-a972-9752ce5a9280", "gmtOffSetMilliseconds": -14400000, "currentPrice": 18.53, "targetHighPrice": 65.0, "targetLowPrice": 23.0, "targetMeanPrice": 43.33, "targetMedianPrice": 45.5, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 278824992, "totalCashPerShare": 3.065, "ebitda": -261476000, "totalDebt": 25798000, "quickRatio": 7.633, "currentRatio": 7.787, "debtToEquity": 6.707, "returnOnAssets": -0.37133998, "returnOnEquity": -0.64311, "freeCashflow": -138401504, "operatingCashflow": -197166000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]